NCT07402161 · RECRUITING
The Signature of Alzheimer's Disease in Subjective Cognitive Decline
This study is testing whether a combination of tools — blood biomarkers, EEG brain recordings, speech analysis, and genetic profiling — can reliably spot early Alzheimer's disease in people who notice memory slipping but still test normally. There is no drug involved. Researchers will feed all the data into a machine-learning model to see which combination best predicts who is on an Alzheimer's trajectory. Phase is unspecified, so it is best described as an observational research study, not a treatment trial.
You may qualify if
- Clinical diagnosis of SCD according to the SCD-I criteria;
- Mini-Mental State Examination (MMSE) score greater than 24, adjusted for age and education level;
- Normal functioning on the Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL) scales.
You're excluded if
- History of head trauma;
- Current neurological and/or systemic diseases;
- Symptoms of psychosis, major depression, or substance use disorder.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-02-11